Other authors have considered this strategy to overcome CA 125 challenges, such as the combination of CA125 and HE4 levels to predict the risk of ovarian cancer in patients with suspected benign ovarian tumors, RMI (Risk of Malignancy Index), and ROMA (Risk of Ovarian Malignancy Algorithm) [49]. Here, MUC16 is linked to ovarian benign neoplasm.